Biogen Idec Inc. (BIIB)

All Comments on BIIB

  • commenter
    Commodity
    Bubble
    Proponent
    Apr 30 05:15 PM
    Is the Commodities Bubble Popping?- Fast Money Recap (4/29/08) [view article]
    It's not popping yet...Helicopter Ben keeps cutting rates.

    We're going to see $150-200 before 90 again. Nothing systemic has changed in this market. But it will crash.     Reply
  • commenter
    Ames
    Tiedeman
    Apr 30 11:48 AM
    My Website
    Is the Commodities Bubble Popping?- Fast Money Recap (4/29/08) [view article]
    USO and OIL are shorts. Buy DUG on the long side.

    Oil is going to under 100.     Reply
  • commenter
    BioInvestor
    Apr 26 08:24 PM
    My Website
    Pfizer Fizzles, Fast Money Recap (4/18/08) [view article]
    I'd suggest no only hold PFE, but buy more. In fact, why not have one share transferred into your name, that way you can participate in the purchase plan, paying no commissions! Reply
  • commenter
    Norman
    Lepoff, M.D.
    Apr 22 12:32 PM
    Pfizer Fizzles, Fast Money Recap (4/18/08) [view article]
    I agree with the Football Geek. Reply
  • commenter
    tom1234
    Apr 22 08:08 AM
    Pfizer Fizzles, Fast Money Recap (4/18/08) [view article]
    adami is good real good ---Finerman makes clear decisions ---good job both of you--Macki good showman ---pete cool down ---you look happy Reply
  • commenter
    CrossProfit
    Apr 22 07:47 AM
    My Website
    Pfizer Fizzles, Fast Money Recap (4/18/08) [view article]
    Regarding Costco (COST) see our previous comment here;
    seekingalpha.com/artic...
    AND MORE TO THE POINT - here;
    seekingalpha.com/artic...

    Regarding AAPL see;
    www.crossprofit.com/vi...
    and comment here;
    seekingalpha.com/artic...

    CrossProfit     Reply
  • commenter
    Football
    Geek
    Apr 21 08:29 PM
    Pfizer Fizzles, Fast Money Recap (4/18/08) [view article]
    Pfizer is a drug company, and they provide research that benefits
    everyone, along with drugs that help people. Sometimes in our rush
    to make a profit, we lose sight of the good a company does. This
    is the nature of the sector, creating drugs takes time and money.
    They have a ton of cash, and will continue to make money for many
    years to come. I'm holding my shares for the long run.     Reply
  • commenter
    stacked up
    Apr 10 09:07 AM
    My Website
    Fast Money Recap, 4/9/08: Airlines MayTake Off [view article]
    Anyone who not only watches this slimiest group of touts/thieves/liars, but actually follows their recommendations, deserves to lose money.
    CNBC reached down into a toilet and came up with this group.
    As if Cramer wasn't bad enough, this den of thieves makes Cramer look sainted.
     Reply
  • commenter
    SeekingAlpha
    Editors
    Apr 06 05:17 AM
    My Website
    General Discussion on BIIB
    Is this a buy or a sell? Reply
  • commenter
    retired
    pharma
    Mar 16 11:03 AM
    My Website
    Pfizer Should Buy Amgen or Wyeth - Credit Suisse [view article]
    do a bunch of small deals would be my option for Pfe! Pharma is changing away from mega deals like the Lipitor Deal they did several years ago. Reason being is Competition in a MC World. In a MC world formulary control becomes the driver.No one pays for a med w/ o proven benefit "Outcomes" in our Brave New World! So you mine for selected Targeted Therapies that you can adroitly market. I see this as the new Pharma paradigm. Watch Pfe buy the Mid Sized biotech who is completing Phase-3 and is before FDA pending approval on 1 or 2 candidates w/ 1 already on the market in an area that is compatible w/ their Marketing/Research Reply
  • commenter
    Donald E.
    L. Johnson
    Mar 06 03:35 PM
    My Website
    Baxter, Biogen Idec & Elan Subjects of Broken Embargoes [view article]
    Journals and conferences embargo papers in an effort to maximize their ability to win publicity for their organizations when the papers are released in the journals and at the meetings. They force researchers to agree to their embargoes as part of their terms when they accept the papers for publication or presentation.

    Since the researchers' careers depend on their publishing records in peer review journals, they play the game. Also, researchers' grants often require that they publish in peer reviewed journals and that they make presentations at major conferences.

    Thus, the intellectual integrity of medical researchers is compromised both by the organizations that fund their research and by the organizations that publish their findings. This is one reason there is so little trust in medical research, medical journals and the information that comes out of major medical conferences. It is so compromised by money and ambition, and it reflects badly on academia and the medial research community.

    That analysts broke the embargoes is only natural. They had access to inside information that they couldn't publish, and that causes disclosure problems for the analysts and the drug companies involved with the SEC and shareholders.

    Researchers should refuse to embargo their findings. Academia should find other ways of measuring and rewarding scholarly work, and securities analysts should continue to break embargoes. Medical journals and conferences have had their days and should go away.     Reply
  • commenter
    bsrichard
    Mar 06 03:32 PM
    Cancer Stocks Hammered Once Again [view article]
    Alan,

    What are your thoughts on Chemokine Therapeutics Corp (CHKT)?

    And Meridian Co LTD (MRDAF)?
    Reply
  • commenter
    bsrichard
    Mar 06 11:48 AM
    Cancer Stocks Hammered Once Again [view article]
    please ignore the comment above. it was posted in the wrong thread.
    Reply
  • commenter
    bsrichard
    Mar 06 11:47 AM
    Cancer Stocks Hammered Once Again [view article]
    Maybe BofA should by this one too.

    Which bank took the highly rated debt at a discount from TMA?     Reply
  • commenter
    Alan
    Brochstein
    Mar 05 07:06 PM
    My Website
    Cancer Stocks Hammered Once Again [view article]
    I don't know the company, but it sure looks interesting. Technically, it would be nice to hold 1.75. The company is seemingly deficient in cash - it would appear that there will be either an equity or debt offering this year. If they become profitable as forecast this year, the stock could get some attention - diagnostics have been hot. Reply
Loading...
Symbols:
Authors:
Quick Links: